This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
The names of the study drug involved in this study is:
– Osimertinib (Tagrisso)
Primary Outcome Measures Progression free survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Secondary Outcome Measures Overall survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Safety[…]
An open-label Phase I/II study, with a dose escalation part (Phase I) and a 2-arm randomized part (Phase II), in patients with recurrent SCLC.
To determine the efficacy of M7824 plus topotecan or temozolomide in relapsed SCLC.
Purpose: The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
Purpose: A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
Purpose: This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer
Purpose CK-301 is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objective of this study is to assess the safety, tolerability and preliminary efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.
Purpose:The goal of this research is to optimize the MRI system to obtain ideal lung images using Hyperpolarized (HP) Noble and Inert Fluorinated Gases as contrast agents. Lung coils tuned to the frequencies of these gases will be used. This study will take place at TBRHSC in the Cardiorespiratory Department and in the Research MRI facility.